Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Kabraji S, Sole X, Huang Y, Bango C, Sgroi D, Loda M, et al. AKT1 quiescent cancer cells in ductal carcinoma in situ of the breast. NPJ Breast Cancer. 2019;5:10.

Son DH, Doan KV, Yang DJ, Sun JS, Kim SK, Kang N, et al. FoxO1 regulates leptin-induced mood behavior by targeting tyrosine hydroxylase. Metabolism. 2019;91:43-52.

Matrai CE, Rand JH, Baergen RN. Absence of Distinct Immunohistochemical Distribution of Annexin A5, C3b, C4d, and C5b-9 in Placentas From Patients With Antiphospholipid Antibodies, Preeclampsia, and Systemic Lupus Erythematosus. Pediatr Dev Pathol. 2019;22(5):431-439.

Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, et al. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. 2019;133(11):1201-1204.

Greenblatt MB, Ono N, Ayturk UM, Debnath S, Lalani S. The Unmixing Problem: A Guide to Applying Single-Cell RNA Sequencing to Bone. J Bone Miner Res. 2019;34(7):1207-1219.

Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, et al. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019;25(22):6839-6851.

Vlismas PP, Heymann JJ, Marboe CC, Jorde UP, Sims DB. Quadravalvular Noninfectious Endocarditis. JACC Case Rep. 2019;1(3):350-354.

Chang R, Tosi U, Voronina J, Adeuyan O, Wu LY, Schweitzer ME, et al. Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy. Neurooncol Adv. 2019;1(1):vdz004.

Garcia-Bermudez J, Baudrier L, Bayraktar EC, Shen Y, La K, Guarecuco R, et al. Squalene accumulation in cholesterol auxotrophic lymphomas prevents oxidative cell death. Nature. 2019;567(7746):118-122.

Zhao Z, Fan J, Hsu Y-, Lyon CJ, Ning B, Hu TY. Extracellular vesicles as cancer liquid biopsies: from discovery, validation, to clinical application. Lab Chip. 2019;19(7):1114-1140.